Please login to the form below

Not currently logged in
Email:
Password:

Scancell appoints Dr Cliff Holloway as CEO

He joins the immunotherapy firm from Benitec Biopharma

Scancell Holdings, a group focused on the development of novel immunotherapies, has appointed Dr Cliff Holloway as its chief executive officer effective 10 January 2018.

Holloway’s new role will see him drive progress of Scancell’s immunotherapy platforms including ImmunoBody and Moditope, and oversee their commercialisation.

He said: “Having cemented a business relationship with Scancell in 2006 I have followed the company’s significant progress with great interest.

“I am delighted to be joining the Scancell team at this exciting time in the company’s evolution and look forward to building on the many achievements to date, and to progressing these important new cancer therapies for patients.”

With over 25 years’ experience in the life sciences industry, Holloway most joins from Benitec Biopharma, where he held the role of chief business and operating officer.

Prior to this, he was chief executive officer and managing director of Sienna Cancer Diagnostics, and has held roles for Immune System Therapeutics and Biosceptre International.

John Chiplin, executive chairman, Scancell, said: “Cliff’s extensive experience and accomplishments speaks volumes and his expertise in cancer therapeutics will be invaluable as we drive our immunotherapy vaccines through the clinic, with the aim to provide new treatment options for patients with debilitating cancers.”

Holloway succeeds Richard Goodfellow, who will remain on the company’s board of directors.

20th October 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics